Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
5
×
life sciences
national blog main
boston blog main
boston top stories
alnylam pharmaceuticals
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
amgen
biotech
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
drugs
fda
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abeona therapeutics
accelerated approval
accent therapeutics
achilles therapeutics
acute hepatic porphyria
akouos
alder biopharmaceuticals
What
drug
5
×
market
5
×
fda
medicine
data
new
patients
pharmaceuticals
sets
advantages
ago
alnylam
approved
bar
battle
bio
bringing
brings
cancer
cannabis
cholesterol
cleared
clears
closer
derivative
eisai
epilepsy
expect
far
filing
flags
form
gamble
gw
gw’s
higher
inched
incidence
interference
lorcaserin
Language
unset
Current search:
drug
×
" clinical trials "
×
market
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
6 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug